Contineum Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
CTNM$10.56+2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net income (loss) | $(27,693) | $30,489 |
| Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 183 | 158 |
| Non-cash operating lease expense | 719 | 701 |
| Stock-based compensation | 4,553 | 1,460 |
| Accretion of debt discount and debt issuance costs | — | (197) |
| Accretion of premiums/discounts on investments, net | (2,875) | (1,477) |
| Change in fair value of warrant liability | 107 | (2) |
| Gain on sale of equipment | (16) | — |
| (Gain) loss on marketable securities | (5) | 22 |
| Change in fair value of investor rights and obligations liability | — | (2,867) |
| Changes in operating assets and liabilities | ||
| Prepaid expenses and other current assets | 1,281 | (1,253) |
| Other long-term assets | 937 | (26) |
| Accounts payable | 763 | 625 |
| Accrued expenses | (635) | 3,199 |
| Operating lease liabilities | 38 | (779) |
| Net cash provided by (used in) operating activities | (22,643) | 30,053 |
| Investing activities | ||
| Purchase of property and equipment | (348) | (105) |
| Proceeds from sale of equipment | 20 | — |
| Purchases of marketable securities | (172,054) | (119,870) |
| Sales and maturities of marketable securities | 112,031 | 45,377 |
| Net cash used in investing activities | (60,351) | (74,598) |
| Financing activities | ||
| Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs | 108,211 | — |
| Proceeds from issuance of Series C convertible preferred stock, net of offering costs | — | 60,138 |
| Principal payments on debt | — | (3,750) |
| Proceeds from exercise of stock options | 148 | 109 |
| Net cash provided by financing activities | 108,359 | 56,497 |
| Net increase in cash and cash equivalents | 25,365 | 11,952 |
| Cash and cash equivalents at beginning of period | 15,526 | 5,569 |
| Cash and cash equivalents at end of period | $40,891 | $17,521 |
| Supplemental disclosure of noncash investing and financing activities | ||
| Conversion of convertible preferred stock to common stock upon initial public offering | $192,620 | $— |
| Reclassification of warrants from liability to equity | $216 | $— |
| Reclassification of deferred offering costs paid in prior year to equity | $343 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.